

# CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS



**BIO074C**  
**March 2016**

Jackson Highsmith  
***Project Analyst***

ISBN: 1-62296-246-X



**BCC Research**  
**49 Walnut Park, Building 2**  
**Wellesley, MA 02481 USA**  
**866-285-7215 (toll-free within the USA),**  
**or (+1) 781-489-7301**  
**[www.bccresearch.com](http://www.bccresearch.com)**  
**[information@bccresearch.com](mailto:information@bccresearch.com)**

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
METHODOLOGY AND INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
SUMMARY TABLE GLOBAL MARKET FOR CNS BIOMARKERS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	7
SUMMARY FIGURE GLOBAL MARKET FOR CNS BIOMARKERS BY APPLICATION, 2013-2020 (\$ MILLIONS)	7
CHAPTER 3 OVERVIEW	11
INTRODUCTION	11
TABLE 1 GLOBAL MARKET FORECAST FOR CNS BIOMARKERS BY AREA, THROUGH 2020 (\$ MILLIONS)	12
TABLE 2 GLOBAL MARKET FOR CNS BIOMARKERS BY AREA, THROUGH 2015 (\$ MILLIONS)	13
TABLE 3 BIOMARKERS IN DRUG DISCOVERY: CNS BIOMARKERS MARKET, THROUGH 2020 (%)	13
BIOMARKERS FOR CANCER	14
TABLE 4 MARKET SHARE OF CNS SUBSEGMENTS, 2015 (\$ MILLIONS/ %)	14
TABLE 5 PERCENTAGE OF PREDICTIVE BIOMARKERS FOR CANCER PATIENTS BY SEGMENT, 2010-2020 (%)	15
TABLE 6 FREQUENCY OF APPROACH IN CLAIMS REVIEW BY PAYERS, 2013-2020 (%)	16
TABLE 7 RELATIVE IMPORTANCE OF REIMBURSEMENT DECISIONS OF TEST FACTORS, 2009-2015 (%)	16
BIOMARKERS FOR NON-ONCOLOGY INDICATIONS	18
DISEASE-SPECIFIC BIOMARKERS AND COMPANION DIAGNOSTICS	19
CSF BIOMARKERS	21
PERIPHERAL BIOMARKERS	22
ULTRA-BLOCKBUSTER	24
TABLE 8 CNS BIOMARKERS	25
TABLE 9 INFORMATION TECHNOLOGY (IT) STRATEGIES	26
BIOMARKERS ON TARGET	26
TABLE 10 INITIAL DESIGNS AND CAPABILITIES	27
ADAPTING TO DATA	27
SAFETY/TOXICOLOGY BIOMARKERS	27
LIVER	28
MUSCLE	28
CARDIAC HYPERTROPHY	28
VASCULAR INJURY	29

TOPIC	PAGE NO.
DOSE SELECTION AND OPTIMIZATION	29
NEW EFFORT AIMED AT DOSE SELECTION	29
IMPROVED MEASUREMENT OF THERAPEUTIC EFFICACY	30
Developing a New Framework for Long-term Addiction Treatment	30
Approach #1: Standard Treatment Patient Outcome Assessment	31
Approach #2: Independent Outcome Assessment Focused on Patient Satisfaction	31
Approach #3: Recovery-Oriented System Model and Healthcare	31
OUTCOME BIOMARKERS AND SURROGATE END POINTS	32
<i>TABLE 11 SUMMARY OF IOM RECOMMENDATIONS FOR A FRAMEWORK FOR EFFECTIVE BIOMARKER EVALUATION</i>	32
<i>TABLE 12 SUMMARY OF IOM RECOMMENDATIONS FOR A FRAMEWORK FOR EFFECTIVE BIOMARKER EVALUATION: SCIENTIFIC PROCESS HARMONIZATION</i>	33
<i>TABLE 13 BENEFITS OF BIOMARKERS AS SURROGATE END POINTS</i>	33
CHALLENGES TO TRAUMATIC BRAIN INJURY (TBI) BIOMARKER DEVELOPMENT	34
<i>TABLE 14 HOW BIOMARKERS MIGHT FACILITATE TBI THERAPY DEVELOPMENT</i>	34
Immediate Action Items	34
EARLY STAGE CLINICAL TRIAL APPLICATIONS	35
SUMMARY OF BIOMARKER CHALLENGES AND OPPORTUNITIES	36
CHALLENGES	38
OPPORTUNITIES	39
PROTEIN BIOMARKER TECHNOLOGY PLATFORMS: HYPOTHESIS-DRIVEN VS HYPOTHESIS-FREE APPROACHES	41
REQUIREMENTS FOR CLINICAL VALIDITY	41
BIOMARKER PROGRESS	42
ENVIRONMENTAL EXPOSURES, EFFECT MODIFIERS, OR RISK FACTORS	42
<i>TABLE 15 CROSS-SECTIONAL INVESTIGATIONS</i>	43
INTERMEDIATE BIOMARKERS	43
SCREENING, DIAGNOSTIC TESTS, AND PROGNOSIS	43
VARIABILITY	44
VALIDITY	44
PRODUCT SUMMARY AND MARKET	46
GENOMICS	46
<i>TABLE 16 GLOBAL MARKETS FOR CNS BIOMARKERS THROUGH 2015 (\$ MILLIONS)</i>	46
Progress in Genomic Biomarker Development	47
Emerging Evidence	47
Democratizing Health Care	48
BIOMARKER ADOPTION BY THE PHARMACEUTICAL INDUSTRY	48
CANCER BIOMARKERS: ADOPTION IS DRIVING GROWTH	52
<i>TABLE 17 CLINICAL PATIENT MONITORING FOR CNS BIOMARKERS, AS COMPARED TO OTHER DISEASES (%)</i>	53
CLINICAL TRIAL BENEFITS: COST AND RISK AVOIDANCE	54
PHASE II TRIALS	54
PHASE IIA BASKET DISCOVERY TRIALS	55
PHASE III TARGETED (ENRICHMENT) DESIGNS	56
PHASE III BIOMARKER STRATIFIED DESIGN	57
PHASE III ADAPTIVE THRESHOLD DESIGN	58
BIOMARKER MARKET FORECAST	59

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 18 GLOBAL MARKET FORECAST FOR CNS BIOMARKERS BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)</i>	59
CHAPTER 4 REGULATORY DYNAMICS, INTELLECTUAL PROPERTY, ETHICAL CONSIDERATIONS	61
INTRODUCTION	61
BIOMARKER LABORATORY REGULATORY SUMMARY	61
DEFINITION OF AN IVD COMPANION DIAGNOSTIC	62
Labeling	64
<i>TABLE 19 PHARMACOGENOMIC BIOMARKERS IN DRUG LABELING</i>	65
REGULATORY PROCESSES FOR NEW TECHNOLOGIES	80
ENSURING SAFETY AND EFFECTIVENESS OF HEALTH TECHNOLOGIES	80
SAFE FOR WIDESPREAD USE?	80
REVIEW IN THE DEVELOPING WORLD	80
ASSAY DEVELOPMENT AND VALIDATION IN DRUG DIAGNOSTIC CO-DEVELOPMENT	81
KEY DRAFT GUIDANCE POINTS FOR IVD COMPANION DIAGNOSTIC DEVICES:	82
SOME RELEVANT FDA GUIDANCE DOCUMENTS FOR CO-DEVELOPMENT	83
PIPELINE FOR BIOMARKER DEVELOPMENT	86
CLINICAL CONCEPTIONS ON THE BIOMARKERS STUDY DESIGN	87
TECHNICAL CONSIDERATIONS REGARDING THE ANALYTICAL SET UP FOR BIOMARKER DEVELOPMENT	87
DISCOVERY OF BIOMARKERS	88
GEL-BASED PROTEOMICS PLATFORMS FOR BIOMARKER DISCOVERY	89
SHOTGUN PROTEOMICS	90
CE-MS	91
STATISTICAL DATA MINING FOR PROTEOMIC BIOMARKER DISCOVERY	91
VERIFICATION OF BIOMARKERS	92
PROTEIN BINDING ASSAYS	92
MASS SPECTROMETRIC QUANTITATIVE APPROACHES	93
PRE-TREATMENT STRATEGIES	93
DATA MINING AND STATISTICAL ANALYSIS	94
BIOINFORMATICS PLATFORMS IN CLINICAL PROTEOMICS	94
APPLICATIONS OF SYSTEMS BIOLOGY---DISEASE DIAGNOSIS AND TREATMENT	94
VALIDATION OF BIOMARKER CANDIDATES	95
APPLICATION OF PROTEOMICS APPROACHES IN BCA BIOMARKER DISCOVERY	97
Analytical Validation of a Companion Diagnostic	97
COMPANION DIAGNOSTIC VALIDATION	98
CLINICAL VALIDATION	99
OVERVIEW OF ESSENTIAL TYPES OF BIOMARKERS	100
<i>TABLE 20 BIOMARKER CATEGORIES AND TYPES</i>	101
OVERVIEW OF ALREADY APPROVED CDX ON THE MARKETS	102
KEY POINTS TO BE ADDRESSED	102
CONSIDERATIONS BEFORE INITIATING THE BIOMARKER DISCOVERY PHASE	103
CONSIDERATIONS ON THE SELECTION AND RANDOMIZATION OF PATIENTS FOR BIOMARKER STUDIES: LOOKING FOR THE 'IDEAL' PATIENTS	103
THE CURRENT STATE OF BIOMARKER DISCOVERY	104

<b>TOPIC</b>	<b>PAGE NO.</b>
PITFALLS AND LIMITATIONS	104
SELECTION OF PATIENTS AND CONTROLS	105
ROLE OF THE FOOD & DRUG ADMINISTRATION	105
FDA GUIDELINES FOR BIOMARKER APPLICATIONS	105
<i>TABLE 21 BIOMARKER QUALIFICATION PROGRAM</i>	107
EUROPEAN MEDICINES AGENCY	108
REGULATORY IMPACT ON DRUG SAFETY	108
INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING	109
Approved Patent Analysis	109
<i>TABLE 22 ANNUAL NUMBER OF PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS IN THE U.S., EUROPE, AND JAPAN, THROUGH 2015 (NUMBER/%)</i>	109
COMPETITIVE LANDSCAPE	109
LATE STAGE CLINICAL TRIALS: COMPETITIVE POSITIONING	110
<i>TABLE 23 GLOBAL MARKET FOR TOTAL CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2020 (\$ MILLIONS)</i>	110
<i>TABLE 24 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY, 2007-2014</i>	111
<i>TABLE 25 REPRESENTATIVE LIST OF APPROVED BIOMARKER PATENTS IN THE U.S., EUROPE, AND JAPAN</i>	114
CHAPTER 5 APPLICATIONS OF CNS BIOMARKERS	119
OVERVIEW	119
<i>TABLE 26 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY THERAPEUTIC AREA, THROUGH 2020 (\$ MILLIONS)</i>	121
CENTRAL NERVOUS SYSTEM	122
<i>TABLE 27 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE</i>	122
CLINICAL BIOMARKERS: THERAPEUTIC DISEASE MARKET FORECAST	123
<i>TABLE 28 GLOBAL MARKET FORECAST FOR CLINICAL STAGE BIOMARKERS, THROUGH 2020 (\$ MILLIONS)</i>	123
<i>TABLE 29 GLOBAL MARKET FORECAST FOR CNS BIOMARKERS IN LATE STAGE CLINICAL USE, THROUGH 2020 (\$ MILLIONS)</i>	123
CHAPTER 6 BIOMARKERS ACTIVELY GUIDING DRUG DEVELOPMENT	125
AN OVERVIEW	125
<i>TABLE 30 RELEVANT CORPORATE ALLIANCE BETWEEN A REFERENCE LAB AND A DRUG DEVELOPMENT COMPANY</i>	126
CHAPTER 7 COMPANY ANALYSIS	128
ABBOTT LABORATORIES INC.	128
COMPANY OVERVIEW	128
PRODUCTS AND SERVICES	128
<i>TABLE 31 ABBOTT'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	128
COMPANY STRATEGY	129
AFFYMETRIX INC.	129
COMPANY OVERVIEW	129
PRODUCTS AND SERVICES	130
<i>TABLE 32 AFFYMETRIX'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	130
COMPANY STRATEGY	130

TOPIC	PAGE NO.
ASTELLAS PHARMA INC.	131
COMPANY OVERVIEW	131
PRODUCTS AND SERVICES	131
<i>TABLE 33 ASTELLAS' REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	132
COMPANY STRATEGY	132
ASTRAZENECA LTD.	132
COMPANY OVERVIEW	132
PRODUCTS AND SERVICES	133
<i>TABLE 34 ASTRAZENECA'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	133
COMPANY STRATEGY	133
BANYAN BIOMARKERS INC.	134
COMPANY OVERVIEW	134
PRODUCTS AND SERVICES	134
<i>TABLE 35 BANYAN'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	134
COMPANY STRATEGY	135
BAYER SCHERING PHARMA AG	135
COMPANY OVERVIEW	135
PRODUCTS AND SERVICES	135
<i>TABLE 36 BAYER SCHERING'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	136
COMPANY STRATEGY	136
BG MEDICINE INC.	138
COMPANY OVERVIEW	138
PRODUCTS AND SERVICES	138
<i>TABLE 37 BIOPHYSICAL REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	138
COMPANY STRATEGY	138
BIOPHYSICAL CORP.	139
COMPANY OVERVIEW	139
PRODUCTS AND SERVICES	139
COMPANY STRATEGY	139
BIOSYSTEMS INTERNATIONAL INC.	140
COMPANY OVERVIEW	140
PRODUCTS AND SERVICES	140
COMPANY STRATEGY	140
BOEHRINGER INGELHEIM GMBH	141
COMPANY OVERVIEW	141
PRODUCTS AND SERVICES	141
<i>TABLE 38 BMS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	141
COMPANY STRATEGY	142
BRISTOL-MYERS SQUIBB CO.	142
COMPANY OVERVIEW	142
PRODUCTS AND SERVICES	142
<i>TABLE 39 BMS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	143
COMPANY STRATEGY	143
CAPRION PROTEOMICS INC.	144
COMPANY OVERVIEW	144

<b>TOPIC</b>	<b>PAGE NO.</b>
PRODUCTS AND SERVICES	144
COMPANY STRATEGY	144
Infectious Diseases	144
Diabetes and Metabolic Disease	145
Oncology	145
DAIICHI SANKYO COMPANY LTD.	145
COMPANY OVERVIEW	145
PRODUCTS AND SERVICES	145
<i>TABLE 40 DAIICHI SANKYO'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	146
COMPANY STRATEGY	146
EISAI CO. LTD.	147
COMPANY OVERVIEW	147
PRODUCTS AND SERVICES	147
<i>TABLE 41 EISAI'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	147
COMPANY STRATEGY	148
ELI LILLY AND COMPANY	148
COMPANY OVERVIEW	148
PRODUCT AND SERVICES	148
<i>TABLE 42 ELI LILLY'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	149
COMPANY STRATEGY	149
EPIGENOMICS AG	149
COMPANY OVERVIEW	150
PRODUCTS AND SERVICES	150
<i>TABLE 43 EPIGENOMICS' REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	150
COMPANY STRATEGY	150
GENEDATA AG	151
COMPANY OVERVIEW	151
PRODUCTS AND SERVICES	151
<i>TABLE 44 GENEDATA'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	151
COMPANY STRATEGY	152
GENENEWS LTD	152
COMPANY OVERVIEW	152
PRODUCTS AND SERVICES	152
COMPANY STRATEGY	152
GLAXOSMITHKLINE	153
COMPANY OVERVIEW	153
PRODUCTS AND SERVICES	153
<i>TABLE 45 GSK'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	153
COMPANY STRATEGY	154
JOHNSON & JOHNSON LTD.	154
COMPANY OVERVIEW	154
PRODUCTS AND SERVICES	155
<i>TABLE 46 JOHNSON &amp; JOHNSON'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	155
COMPANY STRATEGY	155

<b>TOPIC</b>	<b>PAGE NO.</b>
MERCK & CO.	156
COMPANY OVERVIEW	156
PRODUCTS AND SERVICES	156
<i>TABLE 47 MERCK'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	156
COMPANY STRATEGY	157
NOVARTIS AG	157
COMPANY OVERVIEW	157
PRODUCTS AND SERVICES	158
<i>TABLE 48 NOVARTIS' REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	158
COMPANY STRATEGY	158
PFIZER INC.	159
COMPANY OVERVIEW	159
PRODUCTS AND SERVICES	159
<i>TABLE 49 PFIZER'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	159
COMPANY STRATEGY	160
ROCHE LTD	160
COMPANY OVERVIEW	160
PRODUCTS AND SERVICES	161
<i>TABLE 50 ROCHE'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	161
COMPANY STRATEGY	161
SANOFI	162
COMPANY OVERVIEW	162
PRODUCTS AND SERVICES	162
<i>TABLE 51 SANOFI'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	163
COMPANY STRATEGY	163
TAKEDA PHARMACEUTICALS LTD.	164
COMPANY OVERVIEW	164
PRODUCTS AND SERVICES	164
<i>TABLE 52 TAKEDA'S PHARMACEUTICALS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	164
COMPANY STRATEGY	165
TEVA PHARMACEUTICAL INDUSTRIES LTD.	165
COMPANY OVERVIEW	165
PRODUCTS AND SERVICES	166
<i>TABLE 53 TEVA'S PHARMACEUTICAL REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	166
COMPANY STRATEGY	167



**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET FOR CNS BIOMARKERS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	7
TABLE 1 GLOBAL MARKET FORECAST FOR CNS BIOMARKERS BY AREA, THROUGH 2020 (\$ MILLIONS)	12
TABLE 2 GLOBAL MARKET FOR CNS BIOMARKERS BY AREA, THROUGH 2015 (\$ MILLIONS)	13
TABLE 3 BIOMARKERS IN DRUG DISCOVERY: CNS BIOMARKERS MARKET, THROUGH 2020 (%)	13
TABLE 4 MARKET SHARE OF CNS SUBSEGMENTS, 2015 (\$ MILLIONS/ %)	14
TABLE 5 PERCENTAGE OF PREDICTIVE BIOMARKERS FOR CANCER PATIENTS BY SEGMENT, 2010-2020 (%)	15
TABLE 6 FREQUENCY OF APPROACH IN CLAIMS REVIEW BY PAYERS, 2013-2020 (%)	16
TABLE 7 RELATIVE IMPORTANCE OF REIMBURSEMENT DECISIONS OF TEST FACTORS, 2009-2015 (%)	16
TABLE 8 CNS BIOMARKERS	25
TABLE 9 INFORMATION TECHNOLOGY (IT) STRATEGIES	26
TABLE 10 INITIAL DESIGNS AND CAPABILITIES	27
TABLE 11 SUMMARY OF IOM RECOMMENDATIONS FOR A FRAMEWORK FOR EFFECTIVE BIOMARKER EVALUATION	32
TABLE 12 SUMMARY OF IOM RECOMMENDATIONS FOR A FRAMEWORK FOR EFFECTIVE BIOMARKER EVALUATION: SCIENTIFIC PROCESS HARMONIZATION	33
TABLE 13 BENEFITS OF BIOMARKERS AS SURROGATE END POINTS	33
TABLE 14 HOW BIOMARKERS MIGHT FACILITATE TBI THERAPY DEVELOPMENT	34
TABLE 15 CROSS-SECTIONAL INVESTIGATIONS	43
TABLE 16 GLOBAL MARKETS FOR CNS BIOMARKERS THROUGH 2015 (\$ MILLIONS)	46
TABLE 17 CLINICAL PATIENT MONITORING FOR CNS BIOMARKERS, AS COMPARED TO OTHER DISEASES (%)	53
TABLE 18 GLOBAL MARKET FORECAST FOR CNS BIOMARKERS BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	59
TABLE 19 PHARMACOGENOMIC BIOMARKERS IN DRUG LABELING	65
TABLE 20 BIOMARKER CATEGORIES AND TYPES	101
TABLE 21 BIOMARKER QUALIFICATION PROGRAM	107
TABLE 22 ANNUAL NUMBER OF PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS IN THE U.S., EUROPE, AND JAPAN, THROUGH 2015 (NUMBER/%)	109
TABLE 23 GLOBAL MARKET FOR TOTAL CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2020 (\$ MILLIONS)	110
TABLE 24 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY, 2007-2014	111
TABLE 25 REPRESENTATIVE LIST OF APPROVED BIOMARKER PATENTS IN THE U.S., EUROPE, AND JAPAN	114
TABLE 26 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY THERAPEUTIC AREA, THROUGH 2020 (\$ MILLIONS)	121
TABLE 27 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE	122
TABLE 28 GLOBAL MARKET FORECAST FOR CLINICAL STAGE BIOMARKERS, THROUGH 2020 (\$ MILLIONS)	123
TABLE 29 GLOBAL MARKET FORECAST FOR CNS BIOMARKERS IN LATE STAGE CLINICAL USE, THROUGH 2020 (\$ MILLIONS)	123
TABLE 30 RELEVANT CORPORATE ALLIANCE BETWEEN A REFERENCE LAB AND A DRUG DEVELOPMENT COMPANY	126
TABLE 31 ABBOTT'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	128

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 32 AFFYMETRIX'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	130
TABLE 33 ASTELLAS' REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	132
TABLE 34 ASTRAZENECA'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	133
TABLE 35 BANYAN'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	134
TABLE 36 BAYER SCHERING'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	136
TABLE 37 BIOPHYSICAL REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	138
TABLE 38 BMS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	141
TABLE 39 BMS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	143
TABLE 40 DAIICHI SANKYO'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	146
TABLE 41 EISAI'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	147
TABLE 42 ELI LILLY'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	149
TABLE 43 EPIGENOMICS' REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	150
TABLE 44 GENEDATA'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	151
TABLE 45 GSK'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	153
TABLE 46 JOHNSON & JOHNSON'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	155
TABLE 47 MERCK'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	156
TABLE 48 NOVARTIS' REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	158
TABLE 49 PFIZER'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	159
TABLE 50 ROCHE'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	161
TABLE 51 SANOFI'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	163
TABLE 52 TAKEDA'S PHARMACEUTICALS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	164
TABLE 53 TEVA'S PHARMACEUTICAL REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	166

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET FOR CNS BIOMARKERS BY APPLICATION, 2013-2020 (\$ MILLIONS)	7